Track topics on Twitter Track topics that are important to you
Sunnyvale, Aug. 27, 2018 (GLOBE NEWSWIRE) -- August 27, 2018 - Sunnyvale, CA – Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces allergy testing partnerships with multiple providers of allergen immunotherapy products including sub-cutaneous, sublingual, and oral allergy medicines designed to treat patients of allergy and asthma. Allergen immunotherapy, a time-tested clinical approach, can reduce or eliminate allergy and asthma symptoms by lowering the levels of specific cellular proteins known as immunoglobulin E (IgE) molecules that activate the immune system and trigger immune responses. Through these partnerships, doctors prescribing Arrayit allergy tests gain access to a portfolio of safe, effective and convenient allergy medicines for their allergy and asthma patients, including custom immunotherapy products formulated upon review of quantitative allergy test results.
Arrayit recently completed an allergy testing pilot program for a top retail chain, established a nationwide network of 1,700 allergy sales professionals, met with top officials at the United States Food and Drug Administration (FDA) regarding FDA approval of a major product line, reported the sale of clinical instrumentation to the FDA, signed allergy testing contracts with a consortium of 178 medical clinics and received approval for in-store promotions by a major retailer. Arrayit’s new therapeutics partners provide a seamless solution to doctors who diagnose and treat the more than 50 million Americans reporting allergic symptoms annually.
Arrayit CEO Rene Schena states, “Partnering with major allergy therapeutics companies provides proven treatment modalities for physicians who also prescribe Arrayit’s allergy microarray tests. Such test-treatment pairing is designed to afford supervised health and wellness of individual patients through value-based personalized medicine.”
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the research, biotechnology, pharmaceutical, clinical and healthcare sectors through the discovery, development and manufacture of proprietary life science and personalized medicine products and services to advance biomedical research and improve wellness and human health. Please visit www.arrayit.com for more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's public filings.
Public Relations Arrayit Corporation Tel: 408-744-1331 Email: email@example.com Web: www.arrayit.comNEXT ARTICLE
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...
Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...